Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLMO-001 trial of bevacizumab plus modified FOLFOX-6 in initially unresectable or borderline resectable colorectal liver metastases
2011-001364-22Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Roche. Primary endpoint: Objective response rate / tumor shrinkage. Started Dec 2011; status: completed.
02
Drugs
bevacizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-001364-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001364-22.